Skip to content

Injection site reactions on Zepbound, Saxenda, Wegovy and other GLP-1 injections

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

A Zepbound injection site reaction, such as redness, itching or rash where the needle went in, was reported by 6% to 8% of adults (2% on placebo). Six GLP-1 labels report these reactions, including 13.9% on Saxenda (10.5% on placebo), 3.2% on Mounjaro, 1.4% on Wegovy, 0.5% on Trulicity and 0.2% on Ozempic in adult trials. Foundayo and Rybelsus are tablets, so the reaction doesn't apply.

Source: FDA label (DailyMed)

Key takeaways

  • Tell your prescriber or pharmacist about a site reaction that keeps returning, spreads or doesn't settle.
  • Get emergency help for swelling of the face, lips, tongue or throat, trouble breathing or a widespread rash.
  • Every injectable label tells you to move the injection around, though only Saxenda's gives a reason.
  • Read each rate against its own placebo group. Placebo injections cause site reactions too.
  • Never share a multi-dose pen between patients, even with a new needle.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Injection Site Reactions2%6%8%8%

Zepbound: Injection site reactions

In ZEPBOUND-treated patients in a pool of Study 1 and 2, injection site reactions were more frequent in those with anti-tirzepatide antibodies (11.3%) compared to those who did not develop anti-tirzepatide antibodies (1%) [see Clinical Pharmacology (12.6)].

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Injection site reactions

In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Injection site reactions

In clinical trials in adults for weight reduction, 1.4% of WEGOVY-treated patients and 1% of patients receiving placebo experienced injection site reactions (including injection site pruritus, erythema, inflammation, induration, and irritation).

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Injection site reactions

In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC-treated patients.

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Injection Site Reaction10.5%13.9%

Saxenda: Injection site reactions

The most common reactions, each reported by 1% to 2.5% of SAXENDA-treated patients and more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site.

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Injection site reactions

In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If the spot where you injected is red, itchy or firm, tell your prescriber or pharmacist if it keeps returning, spreads or doesn’t settle. Get emergency help for swelling of the face, lips, tongue or throat, trouble breathing or a widespread rash.

An injection site reaction is a local response where the needle went in: redness, itching, a rash or a firm spot. Six of the eight medicines we cover are injected, and all six labels report it. The rates differ widely, and so do the trials behind them.

What each injectable label reports

Each figure is the share of trial patients who reported a site reaction. A placebo group gets an inactive treatment instead of the medicine.

In the label’s table

  • Zepbound (adults with obesity or overweight, two pooled trials of up to 72 weeks): 6% at 5 mg, 8% at 10 mg and 8% at 15 mg, with 2% on placebo.
  • Saxenda (adults, five trials): 13.9%, with 10.5% on placebo. Saxenda is injected once a day. The label adds that the most common reactions, each reported by 1% to 2.5% of Saxenda-treated patients and more commonly than on placebo, were erythema (redness), pruritus (itching) and rash at the injection site.

In the label’s text

  • Mounjaro (adults with type 2 diabetes, pooled placebo-controlled trials): 3.2%, with 0.4% on placebo.
  • Wegovy (adults, weight reduction trials): 1.4%, with 1% on placebo. The label lists the forms: injection site pruritus, erythema, inflammation, induration (hardening) and irritation.
  • Trulicity (adults, placebo-controlled studies): 0.5%, with 0.0% on placebo, with injection-site rash and erythema given as examples.
  • Ozempic (placebo-controlled trials): 0.2% of Ozempic-treated patients, with injection-site discomfort and erythema as examples. The sentence gives no placebo figure.

In pediatric trials

  • Trulicity: 3.9% (2 patients) on 0.75 mg, 3.8% (2 patients) on 1.5 mg and 2.0% (1 patient) on placebo.
  • Saxenda, adolescents aged 12 and older: the table lists injection site pain at 3.2% in both the Saxenda and placebo groups.

Not applicable

Foundayo and Rybelsus are tablets, as are Wegovy tablets and Ozempic tablets. Their labels have no injection site reactions to report.

Why the placebo figure is the key number here

Placebo injections cause site reactions as well, because the needle and the liquid do, whatever is in them. Saxenda’s placebo group reported 10.5%. Wegovy’s reported 1%, four tenths of a point below the treated group.

So the useful way to read each row is the gap between treated and placebo patients in the same trial. Comparing one label’s rate with another’s doesn’t work. The trials enrolled different people on different injection schedules, and they were run separately. We don’t rank the medicines on this.

Antibodies and Zepbound

The Zepbound label reports one further detail. Antibodies are proteins the immune system makes, here against the medicine. In the label’s pooled trials, injection site reactions were more frequent in patients who developed anti-tirzepatide antibodies (11.3%) than in those who didn’t (1%).

What the labels say about where to inject

Each injectable label names the same areas, the abdomen, the thigh and the upper arm, and each tells you to move the injection around:

  • Zepbound, Mounjaro and Trulicity: “Rotate injection sites with each dose.” For Zepbound and Mounjaro, the back of the upper arm is for injections given by another person.
  • Wegovy: “Rotate injection sites with each dose.”
  • Ozempic: use a different injection site each week when injecting in the same body region.
  • Saxenda: rotate sites within the same region “in order to reduce the risk of cutaneous amyloidosis,” lumps of protein that build up under the skin. The Saxenda label also lists cutaneous amyloidosis among reactions reported after approval.

Only Saxenda’s label, in our records, gives a reason for rotating. None says rotation prevents the reactions in the tables above.

When a reaction is more than local

The warnings sections draw the line. Every label warns of serious hypersensitivity (allergic) reactions such as anaphylaxis, a sudden and severe whole-body reaction, and angioedema, swelling under the skin. Mounjaro’s says: “If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve.” Zepbound’s reports that 0.1% of treated patients in its pooled trials had severe hypersensitivity reactions, against none on placebo.

The labels for the multi-dose pens add a separate warning. A pen must never be shared between patients, even with a new needle, because of the risk of passing on blood-borne infections.

When to contact your prescriber

Tell your prescriber or pharmacist about a site reaction that keeps returning, spreads or doesn’t settle. They can also check your injection technique. Get emergency help for swelling of the face, lips, tongue or throat, trouble breathing or a widespread rash.

If you draw doses from a vial, the dosing error checker covers measuring mistakes, which are a separate problem from skin reactions. See also the side effects overview, Zepbound and Saxenda.

Frequently asked questions

Are injection site reactions common with Zepbound?

They're listed in the Zepbound label's table. In two pooled weight reduction trials in adults, 6% of patients on 5 mg, 8% on 10 mg and 8% on 15 mg reported them, compared with 2% on placebo. They were more frequent in patients who developed anti-tirzepatide antibodies (11.3%), proteins the immune system makes against the medicine, than in those who didn't (1%).

What does an injection site reaction look like?

The labels give examples. Wegovy's lists injection site pruritus (itching), erythema (redness), inflammation, induration (hardening) and irritation. Saxenda's names erythema, pruritus and rash at the injection site. Ozempic's mentions injection-site discomfort and erythema, and Trulicity's mentions injection-site rash and erythema. None of the labels in our records says how long these last.

Does rotating injection sites help?

The labels tell you to do it, though most don't say why. Zepbound, Mounjaro, Trulicity and Wegovy say to rotate injection sites with each dose. Ozempic says to use a different site each week when injecting in the same body region. Saxenda says to rotate sites within the same region to reduce the risk of cutaneous amyloidosis, lumps of protein under the skin.

When is a skin reaction after an injection serious?

When it isn't limited to the injection site. The labels warn of serious allergic reactions, including anaphylaxis and angioedema, and say the medicine should be discontinued if one occurs. Saxenda's label says the patient should promptly seek medical advice. Swelling of the face, lips or throat or trouble breathing is an emergency: call 911.

Sources (16)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inject ZEPBOUND subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.”
  2. 2.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose.”
  3. 3.
    FDA label (DailyMed): Trulicity prescribing information, section 2.4
    “Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.”
  4. 4.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification.”
  5. 5.
    FDA label (DailyMed): Wegovy prescribing information, section 2.1
    “Rotate injection sites with each dose.”
  6. 6.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region.”
  7. 7.
    FDA label (DailyMed): Saxenda prescribing information, section 2.1
    “Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm. No dosage adjustment is needed if changing the injection site and/or timing.”
  8. 8.
    FDA label (DailyMed): Saxenda prescribing information, section 2.1
    “Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis”
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.